Rundo, Francesco Bersanelli, Melissa Urzia, Valeria Friedlaender, Alex Cantale, Ornella Calcara, Giacomo Addeo, Alfredo Banna, Giuseppe Luigi
Published in
Clinical genitourinary cancer
Immunotherapy is effective in a small percentage of patients with cancer and no reliable predictive biomarkers are currently available. Artificial Intelligence algorithms may automatically quantify radiologic characteristics associated with disease response to medical treatments. We investigated an innovative approach based on a 3-dimensional (3D) ...
Stokkel, Laura E Stokkel, Marcel P M Donswijk, Maarten L Lahaye, Max J Bekers, Elise M van Rhijn, Bas W G Mertens, Laura S
Published in
Clinical genitourinary cancer
Urachal carcinoma (UrC) is a rare malignancy that often presents at an advanced stage with metastases in up to a quarter of patients. There is no consensus on the optimal form of staging for patients with UrC. In the present study, we evaluated the diagnostic value of 18F-fluorodeoxyglucose-positron emitted tomography/computed tomography (FDG-PET/C...
Morgans, Alicia K Renzulli, Joseph 2nd Olivier, Kara Shore, Neal D
Published in
Clinical genitourinary cancer
Prostate cancer (PC) is primarily a disease of older men. As the risk of neurocognitive decline increases as people age, cognitive dysfunction is a potential complication in men with PC, imposing detrimental effects on functional independence and quality of life. Importantly, risk of cognitive decline may increase with exposure to androgen deprivat...
Li, Eric V Siddiqui, Mohammad R Weiner, Adam B Prizment, Anna E Ryan, Charles J Morgans, Alicia K
Published in
Clinical genitourinary cancer
Combination therapy with docetaxel and androgen deprivation therapy (ADT) prolongs overall survival (OS) in men with metastatic hormone-sensitive prostate cancer. We assessed the benefits and adverse effects of docetaxel and ADT in relation to advancing age. We performed a post hoc analysis of the CHAARTED trial comparing docetaxel and ADT vs. ADT ...
Pelloux-Prayer, Rémi Schiele, Philomène Oudard, Stéphane Gravis, Gwenaëlle Kleinclauss, François Crehange, Gilles Hennequin, Christophe Morgans, Alicia K Geoffrois, Lionel Limat, Samuel
...
Published in
Clinical genitourinary cancer
The optimal therapeutic strategies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer (mCRPC), in terms of cost and effectiveness, remains unknown. This study aims to compare the cost-effectiveness of various potential strategies, from the start of first-line treatment in...
Thomas, Justin J Tward, Jonathan D
Published in
Clinical genitourinary cancer
Adrenocortical carcinoma (ACC) is a rare cancer with few well-powered studies regarding epidemiology or outcomes and even fewer studies to guide an evidence-based management approach. The effect of radiation therapy (RT) is particularly understudied and remains unclear, outside of general oncologic principles. We sought to describe current care pat...
Rini, Brian I Atkins, Michael B Choueiri, Toni K Thomaidou, Despina Rosbrook, Brad Thakur, Maghull Hutson, Thomas E
Published in
Clinical genitourinary cancer
Combined axitinib and immuno-oncology (IO) therapy is approved for first-line advanced renal cell carcinoma. Overlapping toxicities represent a clinical challenge. Calculating the time to resolution (TTR) of common axitinib-related adverse events (AEs) after treatment interruption may help to identify AE etiology and determine appropriate managemen...
Hijab, Adham Curcean, Sebastian Tunariu, Nina Tovey, Holly Alonzi, Roberto Staffurth, John Blackledge, Matthew Padhani, Anwar Tree, Alison Stidwill, Helen
...
Published in
Clinical genitourinary cancer
Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration-resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is unclear. This was a prospective, multicenter phase II study o...
Di Lorenzo, Giuseppe Zappavigna, Silvia Crocetto, Felice Giuliano, Mario Ribera, Dario Morra, Rocco Scafuri, Luca Verde, Antonio Bruzzese, Dario Iaccarino, Simona
...
Published in
Clinical genitourinary cancer
Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral se...
Fern, Lorna A Greenwood, Michelle Smith, Shievon Brand, Susan Coleman, Nicholas Stark, Daniel P Murray, Matthew J
Published in
Clinical genitourinary cancer
MicroRNAs from the miR-371~373 and miR-302/367 clusters, particularly miR-371a-3p, are promising biomarkers for blood-based diagnosis and disease monitoring of malignant germ cell tumors (GCTs) and are nearing clinical implementation. These biomarkers have superior sensitivity and specificity compared with current markers alpha-fetoprotein (AFP) an...
